Seres Therapeutics, Inc. (MCRB) shareholders
Close on Nov 17, 2026Market cap $14.02MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC Joint filing with Abigail P. Johnson (12.80%) | 21,811,697 | 12.80% | 13G (passive) amendment | Dec 31, 2024 |
| Nestlé S.A. | 21,781,753 | – | 13D (active) amendment | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MCRB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Flagship Pioneering Inc. | 1,155,850 | 11.63% | $9.12M | – | 0.59% |
| Vanguard Capital Management LLC | 287,776 | 2.89% | $2.27M | −6,367 | 0.00% |
| Marshall Wace, Llp | 172,245 | 1.73% | $1.36M | +32,706 | 0.00% |
| Vontobel Holding Ltd. | 122,975 | 1.24% | $970.27K | −15,493 | 0.00% |
| BlackRock, Inc. | 111,000 | 1.12% | $875.79K | +8,974 | 0.00% |
| Geode Capital Management, LLC | 79,974 | 0.80% | $631.30K | +5,139 | 0.00% |
| Susquehanna International Group, Llp | 58,328 | 0.59% | $460.21K | −47,011 | 0.00% |
| Vanguard Fiduciary Trust Co | 48,685 | 0.49% | $384.13K | +9,042 | 0.00% |
| State Street Corp | 33,901 | 0.34% | $267.48K | – | 0.00% |
| Lion Point Capital, LP | 31,570 | 0.32% | $249.09K | – | 1.19% |
| Charles Schwab Investment Management Inc | 31,049 | 0.31% | $244.98K | −581 | 0.00% |
| American Century Companies Inc | 28,313 | 0.28% | $223.39K | −34,003 | 0.00% |
| XTX Topco Ltd | 20,732 | 0.21% | $163.58K | New | 0.00% |
| Goldman Sachs Group Inc | 15,229 | 0.15% | $120.16K | New | 0.00% |
| Northern Trust Corp | 14,765 | 0.15% | $116.50K | – | 0.00% |
| Invesco Ltd. | 12,974 | 0.13% | $102.37K | −1,573 | 0.00% |
| Morgan Stanley | 12,138 | 0.12% | $95.77K | −9,562 | 0.00% |
| Citadel Advisors LLC | 10,504 | 0.11% | $82.88K | New | 0.00% |
| Simplex Trading, LLC | 4,598 | 0.05% | $36.28K | +1,528 | 0.00% |
| SBI Securities Co., Ltd. | 4,182 | 0.04% | $33.00K | +700 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 36 | 2M | 22.9% | 8 / 7 | 12 / 5 | 0M | 0M |
| Q1 2026 | 33 | 2M | 23.2% | 5 / 10 | 8 / 7 | 0M | 0M |
| Q4 2025 | 36 | 2M | 24.6% | 9 / 14 | 7 / 5 | 0M | 0M |
| Q3 2025 | 32 | 2M | 21.4% | 9 / 11 | 7 / 10 | 0M | 0M |
| Q2 2025 | 33 | 2M | 23.1% | 32 / 0 | 1 / 3 | 2M | 0M |
| Q1 2025 | 4 | 0M | 0.1% | 4 / 0 | 0 / 0 | 0M | 0M |
| Q1 2021 | 0 | 0M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q4 2020 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
32 funds held MCRB in Q1 2026, 68% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of MCRB | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 206,170 | 2.07% | $1.63M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 75,849 | 0.76% | $598.45K | 0.00% | Jun 30, 2026 |
| Avantis U.S. Small Cap Value ETF | 37,364 | 0.38% | $273.50K | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 31,077 | 0.31% | $227.48K | 0.00% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 26,335 | 0.26% | $192.77K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 25,389 | 0.26% | $200.32K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 13,870 | 0.14% | $101.53K | 0.00% | May 31, 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 12,914 | 0.13% | $62.37K | 0.00% | Jul 31, 2026 |
| Fidelity Series Total Market Index Fund | 10,143 | 0.10% | $74.25K | 0.00% | May 31, 2026 |
| Goldman Sachs Absolute Return Tracker Fund | 10,065 | 0.10% | $79.41K | 0.00% | Jun 30, 2026 |
| U.S. Micro Cap Portfolio | 7,662 | 0.08% | $37.01K | 0.00% | Jul 31, 2026 |
| Ultra-Small Company Market Fund | 7,500 | 0.08% | $59.18K | 0.04% | Jun 30, 2026 |
| WisdomTree U.S. SmallCap Fund | 7,058 | 0.07% | $55.69K | 0.01% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 5,666 | 0.06% | $41.48K | 0.00% | May 31, 2026 |
| Avantis U.S. Small Cap Equity ETF | 5,277 | 0.05% | $38.63K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Richard N. Kender | See Remarks, Director | 63,492 | 0.64% | Jul 10, 2026 |
| Thomas DesRosier | See Remarks | 8,258 | 0.08% | Nov 17, 2026 |
| Kelly Brady | See Remarks | 8,775 | 0.09% | Nov 17, 2026 |
| Matthew R. Henn | See Remarks | 8,132 | 0.08% | Nov 17, 2026 |
| Marella Thorell | See Remarks | – | – | Jul 10, 2026 |
| Teresa L. Young | See Remarks | 8,557 | 0.09% | Feb 18, 2026 |
| Moltke Lisa von | See Remarks | 39,875 | 0.40% | Feb 19, 2025 |
| Eric D. Shaff | Director | 12,936 | 0.13% | Nov 17, 2026 |
| Stephen Berenson | Director | 3,589 | 0.04% | Jul 10, 2026 |
| Robert L. Rosiello | Director | – | – | Jul 10, 2026 |
| Dennis A. Ausiello | Director | – | – | Jul 10, 2026 |
| Willard H. Dere | Director | 31,746 | 0.32% | Jul 10, 2026 |
| Claire Fraser | Director | – | – | Jul 10, 2026 |
| Kurt Graves | Director | – | – | Jul 10, 2026 |
| Paul Biondi | Director | 47,619 | 0.48% | Apr 11, 2025 |
| Hans-Juergen Woerle | Director | – | – | Feb 6, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kelly Brady See Remarks | Nov 16, 2026 | Sale(10b5-1 plan) | −85 | $1.38 | $117 | 8,775 |
| Thomas DesRosier See Remarks | Nov 16, 2026 | Sale(10b5-1 plan) | −103 | $1.38 | $142 | 8,258 |
| Eric D. Shaff Director | Nov 16, 2026 | Sale(10b5-1 plan) | −287 | $1.38 | $396 | 12,936 |
| Matthew R. Henn See Remarks | Nov 16, 2026 | Sale(10b5-1 plan) | −101 | $1.38 | $139 | 8,132 |
| Kelly Brady See Remarks | Nov 15, 2026 | Option exercise | +181 | – | – | 8,860 |
| Thomas DesRosier See Remarks | Nov 15, 2026 | Option exercise | +244 | – | – | 8,361 |
| Eric D. Shaff Director | Nov 15, 2026 | Option exercise | +724 | – | – | 13,223 |
| Matthew R. Henn See Remarks | Nov 15, 2026 | Option exercise | +238 | – | – | 8,233 |
| Kelly Brady See Remarks | Aug 17, 2026 | Sale(10b5-1 plan) | −64 | $4.55 | $291 | 8,679 |
| Thomas DesRosier See Remarks | Aug 17, 2026 | Sale(10b5-1 plan) | −82 | $4.55 | $373 | 8,117 |
| Eric D. Shaff Director | Aug 17, 2026 | Sale(10b5-1 plan) | −263 | $4.55 | $1.20K | 12,499 |
| Matthew R. Henn See Remarks | Aug 17, 2026 | Sale(10b5-1 plan) | −81 | $4.55 | $369 | 7,995 |
| Kelly Brady See Remarks | Aug 15, 2026 | Option exercise | +181 | – | – | 8,743 |
| Thomas DesRosier See Remarks | Aug 15, 2026 | Option exercise | +245 | – | – | 8,199 |
| Eric D. Shaff Director | Aug 15, 2026 | Option exercise | +722 | – | – | 12,762 |
| Matthew R. Henn See Remarks | Aug 15, 2026 | Option exercise | +238 | – | – | 8,076 |
| Thomas DesRosier See Remarks | May 18, 2026 | Sale(10b5-1 plan) | −79 | $7.53 | $595 | 7,954 |
| Kelly Brady See Remarks | May 18, 2026 | Sale | −59 | $7.53 | $444 | 8,562 |
| Eric D. Shaff Director | May 18, 2026 | Sale(10b5-1 plan) | −259 | $7.53 | $1.95K | 12,040 |
| Matthew R. Henn See Remarks | May 18, 2026 | Sale(10b5-1 plan) | −77 | $7.53 | $580 | 7,838 |
| Thomas DesRosier See Remarks | May 15, 2026 | Option exercise | +244 | – | – | 8,033 |
| Kelly Brady See Remarks | May 15, 2026 | Option exercise | +180 | – | – | 8,621 |
| Eric D. Shaff Director | May 15, 2026 | Option exercise | +722 | – | – | 12,299 |
| Matthew R. Henn See Remarks | May 15, 2026 | Option exercise | +238 | – | – | 7,915 |
| Teresa L. Young See Remarks | Feb 15, 2026 | Sale(10b5-1 plan) | −75 | $8.47 | $635 | 8,557 |
| Teresa L. Young See Remarks | Feb 15, 2026 | Option exercise | +231 | – | – | 8,632 |
| Thomas DesRosier See Remarks | Feb 15, 2026 | Option exercise | +244 | – | – | 7,867 |
| Thomas DesRosier See Remarks | Feb 15, 2026 | Sale(10b5-1 plan) | −78 | $8.47 | $661 | 7,789 |
| Eric D. Shaff Director | Feb 15, 2026 | Sale(10b5-1 plan) | −259 | $8.47 | $2.19K | 11,577 |
| Eric D. Shaff Director | Feb 15, 2026 | Option exercise | +723 | – | – | 11,836 |
| Matthew R. Henn See Remarks | Feb 15, 2026 | Sale(10b5-1 plan) | −89 | $8.47 | $754 | 7,677 |
| Matthew R. Henn See Remarks | Feb 15, 2026 | Option exercise | +239 | – | – | 7,766 |
| Thomas DesRosier See Remarks | Nov 15, 2025 | Sale(10b5-1 plan) | −76 | $17.30 | $1.31K | 7,623 |
| Thomas DesRosier See Remarks | Nov 15, 2025 | Option exercise | +112 | – | – | 7,699 |
| Thomas DesRosier See Remarks | Nov 15, 2025 | Option exercise | +132 | – | – | 7,587 |
| Teresa L. Young See Remarks | Nov 15, 2025 | Option exercise | +132 | – | – | 9,345 |
| Teresa L. Young See Remarks | Nov 15, 2025 | Option exercise | +98 | – | – | 9,443 |
| Teresa L. Young See Remarks | Nov 15, 2025 | Option exercise | +3,998 | – | – | 9,213 |
| Teresa L. Young See Remarks | Nov 15, 2025 | Sale(10b5-1 plan) | −1,042 | $17.30 | $18.03K | 8,401 |
| Matthew R. Henn See Remarks | Nov 15, 2025 | Option exercise | +140 | – | – | 8,686 |
| Matthew R. Henn See Remarks | Nov 15, 2025 | Option exercise | +3,998 | – | – | 8,546 |
| Matthew R. Henn See Remarks | Nov 15, 2025 | Option exercise | +98 | – | – | 8,784 |
| Matthew R. Henn See Remarks | Nov 15, 2025 | Sale(10b5-1 plan) | −1,257 | $17.30 | $21.75K | 7,527 |
| Eric D. Shaff Director | Nov 15, 2025 | Option exercise | +390 | – | – | 10,999 |
| Eric D. Shaff Director | Nov 15, 2025 | Option exercise | +331 | – | – | 11,330 |
| Eric D. Shaff Director | Nov 15, 2025 | Sale(10b5-1 plan) | −217 | $17.30 | $3.75K | 11,113 |
| Teresa L. Young See Remarks | Aug 18, 2025 | Sale(10b5-1 plan) | −59 | $16.65 | $982 | 5,215 |
| Thomas DesRosier See Remarks | Aug 18, 2025 | Sale(10b5-1 plan) | −76 | $16.65 | $1.27K | 7,455 |
| Eric D. Shaff Director | Aug 18, 2025 | Sale(10b5-1 plan) | −217 | $16.65 | $3.61K | 10,609 |
| Matthew R. Henn See Remarks | Aug 18, 2025 | Sale(10b5-1 plan) | −73 | $16.65 | $1.22K | 4,548 |
| Teresa L. Young See Remarks | Aug 15, 2025 | Option exercise | +97 | – | – | 5,274 |
| Teresa L. Young See Remarks | Aug 15, 2025 | Option exercise | +133 | – | – | 5,177 |
| Thomas DesRosier See Remarks | Aug 15, 2025 | Option exercise | +133 | – | – | 7,420 |
| Thomas DesRosier See Remarks | Aug 15, 2025 | Option exercise | +111 | – | – | 7,531 |
| Eric D. Shaff Director | Aug 15, 2025 | Option exercise | +391 | – | – | 10,493 |
| Eric D. Shaff Director | Aug 15, 2025 | Option exercise | +333 | – | – | 10,826 |
| Matthew R. Henn See Remarks | Aug 15, 2025 | Option exercise | +141 | – | – | 4,524 |
| Matthew R. Henn See Remarks | Aug 15, 2025 | Option exercise | +97 | – | – | 4,621 |
| Teresa L. Young See Remarks | May 16, 2025 | Sale(10b5-1 plan) | −63 | $7.28 | $459 | 5,044 |
| Matthew R. Henn See Remarks | May 16, 2025 | Sale(10b5-1 plan) | −77 | $7.28 | $561 | 4,383 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Seres Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 10,817 shares on Oct 2, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Teresa L. Young Officer | May 19, 2026 | 167 | $1.28K | May 19, 2026 | Restricted Stock |
| Teresa L. Young Officer | Mar 17, 2026 | 8,553 | $77.97K | Mar 17, 2026 | Restricted and Performance Shares |
See a number that looks wrong?